HABEEB LAWAL

HABEEB LAWAL

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Global Health Science
Verified
Journal Article
Open access
PDF file
ARAbdulrahman Olamilekan Raji
Abdulrahman Olamilekan Raji
HLHABEEB LAWAL
HABEEB LAWAL
ZSZainab Ajoke Suleiman
Zainab Ajoke Suleiman
AOAisha Eniola Olayiwola
Aisha Eniola Olayiwola
WMWahab Muiz
Wahab Muiz
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
Raji AO, et al. J Glob Health Sci. 2025 Dec;8:e2. https://doi.org/10.35500/jghs.2026.8.e2

4 February 2026 in One Health Advances
Verified
Journal Article
Open access
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
Uthman Okikiola AdebayoUthman Okikiola Adebayo
Uthman Okikiola Adebayo
HLHABEEB LAWAL
HABEEB LAWAL
AGAhishakiye Gilbert
Ahishakiye Gilbert
FLFaiazul Haque Lamem
Faiazul Haque Lamem
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Vector-borne and zoonotic diseases (VBZDs) remain a critical global health challenge, disproportionately affecting low- and middle-income countries and driving significant morbidity, mortality, and economic loss. This review synthesizes emerging evidence on nano-enabled smart drug delivery system (SDDS) within the One Health framework, emphasizing their role in advancing targeted therapy, controlled release, and theranostics for VBZD management. Nano-enabled platforms such as liposomes, polymeric nanoparticles, nanogels, metal–organic frameworks, and biomimetic carriers are designed for stimuli-responsive and site-specific delivery, enhancing therapeutic precision, lowering dosing frequency, and reducing the risk of drug resistance. Controlled-release formulations of agents such as artemisinin derivatives, amphotericin B, and ivermectin have demonstrated superior efficacy in the treatment of malaria and leishmaniasis, and in vector control applications. Targeted delivery strategies extend beyond human therapies to address viral reservoirs, infected macrophages, and arthropod vectors, highlighting the cross-species applications central to One Health. Theranostic innovations combine imaging and therapy to enable early disease detection, real-time monitoring, and the design of adaptive treatment strategies. Applications span human, animal, and environmental domains, from nanovaccines and veterinary antimicrobials to nanoparticle-based larvicides and biosensors for vector surveillance. Future directions underscore the integration of AI-driven nanodesign, scalable and eco-friendly synthesis, and harmonized regulatory frameworks to increase accessibility in resource-limited settings. Although clinical trials are limited, ongoing translational efforts indicate the transformative potential of nanomedicine in VBZD control. Ultimately, integrating nano-enabled SDDS into a One Health framework provides a sustainable and collaborative approach to reduce the global burden of zoonotic and vector-borne diseases.

1 January 2025 in Journal of Global Health Science
Verified
Journal Article
Open access
ARAbdulrahman Olamilekan Raji
Abdulrahman Olamilekan Raji
HLHABEEB LAWAL
HABEEB LAWAL
ZSZainab Ajoke Suleiman
Zainab Ajoke Suleiman
AOAisha Eniola Olayiwola
Aisha Eniola Olayiwola
WMWahab Muiz
Wahab Muiz
ASAbdulhakeem Olarewaju Sulyman
Abdulhakeem Olarewaju Sulyman
Vector-borne and zoonotic diseases (VBZDs) represent over 75% of emerging infections globally and continue to impose severe health and economic burdens, especially in lowand middle-income countries. This review examines integrative One Health strategies for the surveillance, control, and prevention of VBZDs, emphasizing the interconnectedness of human, animal, and environmental health. Using thematic synthesis, evidence from multidisciplinary studies were analyzed to identify effective interventions and persistent challenges. The findings reveal that the environmental, socioeconomic, behavioral, climate change, and cultural factors have contributed to the emergence and global spread of these diseases, rendering public health efforts ineffective with fragmented surveillance systems, weak governance, and inequitable access impeding early outbreak detection and coordinated responses. However, hybrid and digital surveillance models, including artificial intelligencedriven and genomic tools, have demonstrated improved predictive capacity and real-time data sharing. Integrated vector management approaches combining biological, chemical, environmental measures and effective governance mechanisms show enhanced sustainability when coupled with community participation. To protect communities and reduce the burden, we recommend strengthened policy and financing frameworks such as multisectoral coordination committees, pooled One Health budgets, and legally mandated governance, promoting equitable community-driven approaches, incorporating gender-sensitive, participatory, and indigenous knowledge-based approaches. The review highlights that

25 August 2025 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
HLHABEEB LAWAL
HABEEB LAWAL
ARAbdulrahman Olamilekan Raji
Abdulrahman Olamilekan Raji
AOAisha Eniola Olayiwola
Aisha Eniola Olayiwola
ZSZainab Ajoke Suleiman
Zainab Ajoke Suleiman
WMWahab Muiz
Wahab Muiz
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
Cancer immunotherapy is one of the renowned therapeutic approaches worldwide, where its intervention has scaled further than conventional therapy. This review targets oncology researchers, immunotherapy clinicians, and public health policymakers and aims to address novel strategies for overcoming the barriers that exploit the implementation of interleukin-12 (IL-12) in cancer immunotherapy. Moreover, it emphasizes the translational challenges and clinical implications for global health interventions. IL-12 cytokine therapy is a specialized type of cancer immunotherapy that involves the systemic or local administration of IL-12 to the targeted tumor microenvironment. Over the years, IL-12 therapy has shown a promising approach in its therapeutic potential in the treatment of various cancer diseases. The molecular structure of IL-12 depicts its potential for stimulating the immune system. IL-12 enhances the production of interferon-gamma (IFN-γ), a specialized cytokine used for the potential treatment of malignant melanoma and other cancer diseases. However, despite its potent antitumor effects, IL-12 therapy has been limited by considerable toxicity observed in preclinical studies, raising concerns about its safety profile. To fully harness IL-12’s therapeutic potential, researchers should prioritize translational studies that mitigate toxicity and improve delivery mechanisms. This includes innovative approaches such as vector-based delivery systems (e.g., viral vectors and nanoparticle carriers), localized gene therapy platforms, and synergistic combination regimens that reduce systemic exposure while enhancing efficacy. Policymakers should promote flexible regulatory frameworks to accommodate adaptive clinical trial designs, while funding bodies are encouraged to support high-impact translational research that accelerates the safe clinical application of IL-12 and similar immunotherapeutic agents.